Kaposi Sarcoma Market Outlook, Top Key Players, Industry Growth Analysis and Forecast to 2022
Kaposi Sarcoma Market report on is foretold to provide a robust support for industry players to lay a solid foundation for their business growth. It includes a comprehensive evaluation of the market’s growth status and market risk. Furthermore, it provides detail industry analysis - porter’s, market variables, trends & key opportunities.
Kaposi Sarcoma Market report on is foretold to provide a robust support for industry players to lay a solid foundation for their business growth. It includes a comprehensive evaluation of the market’s growth status and market risk. Furthermore, it provides detail industry analysis - porter’s, market variables, trends & key opportunities.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Browse Full Research Report @<br />
https://www.millioninsights.com/industry-reports/<strong>Kaposi</strong>-sarcoma-ks-market<br />
KS can cause serious problems or even become life treating when the lesions are in the lungs, liver,<br />
or in digestive tract. The means that the when KS occurs in someone is infected with HIV.<br />
Chemotherapy, immunotherapy, <strong>and</strong> antiretroviral therapy (HAART) are the key treatment methods<br />
for <strong>Kaposi</strong> sarcoma. The HAART therapy emerged as the leading segment owing <strong>to</strong> the high<br />
incidence of AIDS-related <strong>Kaposi</strong> sarcoma globally. HAART therapy includes the combination of<br />
reverse transcriptase (RT) inhibi<strong>to</strong>rs, fusion inhibi<strong>to</strong>rs, <strong>and</strong> protease inhibi<strong>to</strong>rs. Chemotherapy is<br />
likely <strong>to</strong> grow at the fastest pace during the forecast period due <strong>to</strong> the high cost of the treatment<br />
<strong>and</strong> the increasing adoption by immunocompentent patients.<br />
The leading chemotherapy drugs include paclitaxel, liposomal doxorubicin <strong>and</strong> daunorubicin,<br />
bleomicin <strong>and</strong> vincristine. Immunotherapy consists of interferon alfa; which is the first biological<br />
drug approved by the FDA <strong>to</strong> the treatment of <strong>Kaposi</strong> sarcoma. Patients with good immune<br />
functions show effectiveness. However, immune compromised patients rarely respond <strong>to</strong> this<br />
therapy. The therapy accounted for the least share in the global market. <strong>Kaposi</strong> <strong>Sarcoma</strong> <strong>Market</strong> by<br />
Type of Treatment is segmented in<strong>to</strong> Chemotherapy, Liposomal Anthracyclines, Alkaloids,<br />
Immunotherapy, HAART. <strong>Kaposi</strong> <strong>Sarcoma</strong> <strong>Market</strong> by Distribution Channel is segmented in<strong>to</strong><br />
Hospitals, Cancer Research Institutes, Multispecialty Clinics, Ambula<strong>to</strong>ry Surgical Centers.<br />
Request Sample Copy of this <strong>Market</strong> Research @<br />
https://www.millioninsights.com/industry-reports/<strong>Kaposi</strong>-sarcoma-ks-market/request-sample<br />
<strong>Kaposi</strong> <strong>Sarcoma</strong> <strong>Market</strong> by Geographical Region is segmented in<strong>to</strong> North America, Latin America,<br />
Europe, Asia-Pacific, <strong>and</strong> the Middle East <strong>and</strong> Africa. North America contributed <strong>to</strong> the major share<br />
in the <strong>Kaposi</strong> sarcoma market in 2015. Due <strong>to</strong> the presence of key market players <strong>and</strong> the increasing<br />
cost of drugs; the growth of the market is also driven by the easy availability of drugs <strong>and</strong> a high<br />
diagnosis rate of the malignancy. The high cost of the therapy is a deterrent <strong>to</strong> patients in<br />
developing regions such as Asia Pacific <strong>and</strong> the Middle East <strong>and</strong> Africa <strong>and</strong> this limits its adoption. A<br />
limited number of approved biologics is also a prominent fac<strong>to</strong>r restraining the growth of the<br />
immunotherapy segment. The Middle East <strong>and</strong> Africa are expected <strong>to</strong> exp<strong>and</strong> at the highest CAGR<br />
during the forecast period owing <strong>to</strong> the high incidence <strong>and</strong> prevalence of KS in Eastern Africa. The<br />
trend is consistent with the geographic variations of the HIV/AIDS epidemic. The key players include<br />
Aphios Corporation, AstraZeneca Plc, Biogenomics Limited, <strong>and</strong> CytRx Corporation. Eli Lilly <strong>and</strong> Co.,